The effect of propofol on chemosensitivity of paclitaxel in cervical cancer cells.
cervical cancer
paclitaxel
propofol
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
06
04
2023
received:
09
06
2022
accepted:
30
04
2023
medline:
21
7
2023
pubmed:
10
5
2023
entrez:
10
5
2023
Statut:
ppublish
Résumé
Propofol is a drug with potential anticancer effect. This study aimed to explore the effect of propofol on chemosensitivity of cervical cancer cells to paclitaxel. HeLa and CaSki cells were selected for drug experiments. Cell viability was evaluated via CCK-8 assay, and the combination index (CI) was calculated by CompuSyn software. A clinically relevant concentration and IC30 of propofol were selected in combination with 5 nM paclitaxel. BrdU incorporation, transwell, and flow cytometry assays were utilized to evaluate cell proliferation, migration, invasion, and apoptosis. The expression of β-tubulin, stathmin 1, and GAPDH proteins was evaluated by Western blot. The stathmin 1 cDNA plasmid was used to establish stathmin 1-overexpressing CaSki cells. At clinically relevant concentrations (0-80 μM), propofol did not affect cancer cell viability, but high concentrations (100-800 μM) reduced cell viability. The CI values of propofol with IC30 (200 μM in HeLa; 400 μM in CaSki) combined with 5 nM paclitaxel were <1. The effect of propofol with IC30 combined with paclitaxel on cell proliferation, migration, invasion, and apoptosis were stronger than individual effect, while 30 μM propofol had no effect. The Western blot results showed 30 μM propofol did not affect β-tubulin and stathmin 1 expression in cells, although paclitaxel upregulated β-tubulin expression while downregulating stathmin 1 expression. Compared with paclitaxel alone, cotreatment with propofol at its IC30 and paclitaxel decreased stathmin 1 expression but had no effect on β-tubulin expression. High stathmin 1 expression weakened the effect of paclitaxel on cell viability and apoptosis, while propofol partially reversed these effect. Propofol at clinically relevant concentrations had no effect on the malignant biological behaviors of cervical cancer cells, while propofol at high concentrations decreased.Propofol with IC30 and paclitaxel had synergetic effect on cancer cells through a reduction in stathmin 1 expression.
Sections du résumé
BACKGROUND
Propofol is a drug with potential anticancer effect. This study aimed to explore the effect of propofol on chemosensitivity of cervical cancer cells to paclitaxel.
METHODS
HeLa and CaSki cells were selected for drug experiments. Cell viability was evaluated via CCK-8 assay, and the combination index (CI) was calculated by CompuSyn software. A clinically relevant concentration and IC30 of propofol were selected in combination with 5 nM paclitaxel. BrdU incorporation, transwell, and flow cytometry assays were utilized to evaluate cell proliferation, migration, invasion, and apoptosis. The expression of β-tubulin, stathmin 1, and GAPDH proteins was evaluated by Western blot. The stathmin 1 cDNA plasmid was used to establish stathmin 1-overexpressing CaSki cells.
RESULTS
At clinically relevant concentrations (0-80 μM), propofol did not affect cancer cell viability, but high concentrations (100-800 μM) reduced cell viability. The CI values of propofol with IC30 (200 μM in HeLa; 400 μM in CaSki) combined with 5 nM paclitaxel were <1. The effect of propofol with IC30 combined with paclitaxel on cell proliferation, migration, invasion, and apoptosis were stronger than individual effect, while 30 μM propofol had no effect. The Western blot results showed 30 μM propofol did not affect β-tubulin and stathmin 1 expression in cells, although paclitaxel upregulated β-tubulin expression while downregulating stathmin 1 expression. Compared with paclitaxel alone, cotreatment with propofol at its IC30 and paclitaxel decreased stathmin 1 expression but had no effect on β-tubulin expression. High stathmin 1 expression weakened the effect of paclitaxel on cell viability and apoptosis, while propofol partially reversed these effect.
CONCLUSION
Propofol at clinically relevant concentrations had no effect on the malignant biological behaviors of cervical cancer cells, while propofol at high concentrations decreased.Propofol with IC30 and paclitaxel had synergetic effect on cancer cells through a reduction in stathmin 1 expression.
Identifiants
pubmed: 37162289
doi: 10.1002/cam4.6064
pmc: PMC10358199
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Propofol
YI7VU623SF
Tubulin
0
Stathmin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14403-14412Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Anticancer Res. 2018 Feb;38(2):939-944
pubmed: 29374725
BMC Cancer. 2018 Dec 14;18(1):1252
pubmed: 30547768
Hepatobiliary Pancreat Dis Int. 2013 Jun;12(3):305-9
pubmed: 23742776
Trends Cell Biol. 2016 Oct;26(10):766-775
pubmed: 27344407
J Healthc Eng. 2021 Dec 16;2021:2704753
pubmed: 34956562
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancer Med. 2023 Jul;12(13):14403-14412
pubmed: 37162289
Front Oncol. 2022 Mar 28;12:837974
pubmed: 35419287
Gynecol Oncol. 2017 Aug;146(2):247-253
pubmed: 28532857
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Expert Opin Pharmacother. 2020 Apr;21(6):663-677
pubmed: 32037907
Biol Res. 2018 Jun 8;51(1):16
pubmed: 29880026
Drug Des Devel Ther. 2019 Nov 18;13:3919-3928
pubmed: 31819366
Expert Opin Drug Metab Toxicol. 2019 Aug;15(8):671-682
pubmed: 31340683
Pharmacol Ther. 1984;25(1):83-125
pubmed: 6149569
Mini Rev Med Chem. 2021;21(10):1237-1268
pubmed: 33319669
Cell Oncol (Dordr). 2014 Feb;37(1):53-67
pubmed: 24306928
J Pharmacol Sci. 2018 May;137(1):20-29
pubmed: 29699771
Aging (Albany NY). 2021 Nov 13;13(21):24464-24475
pubmed: 34775376
Tissue Cell. 2022 Feb;74:101680
pubmed: 34808429
BMC Cancer. 2021 Sep 1;21(1):981
pubmed: 34470602
Invest New Drugs. 2020 Jun;38(3):899-908
pubmed: 31441020
Thorac Cancer. 2021 Mar;12(6):824-834
pubmed: 33506582
Mol Cell Biochem. 2021 Jan;476(1):45-55
pubmed: 32833118
Front Pharmacol. 2022 Apr 20;13:816432
pubmed: 35517791
Clin Obstet Gynecol. 2020 Mar;63(1):3-11
pubmed: 31815773
Signal Transduct Target Ther. 2021 Feb 1;6(1):42
pubmed: 33526768
Curr Oncol Rep. 2020 Jan 27;22(1):7
pubmed: 31989322
Protoplasma. 2017 May;254(3):1163-1173
pubmed: 27943021
Expert Opin Ther Targets. 2011 Nov;15(11):1249-66
pubmed: 21978024
Am J Cancer Res. 2021 Apr 15;11(4):1446-1462
pubmed: 33948367
Toxicol Res (Camb). 2021 Jun 14;10(4):696-705
pubmed: 34745557
Front Med (Lausanne). 2021 Aug 11;8:658926
pubmed: 34458282
Eur Rev Med Pharmacol Sci. 2013 Jul;17(13):1722-9
pubmed: 23852894
Genes Genomics. 2021 Jul;43(7):807-814
pubmed: 33893626
Front Mol Neurosci. 2018 Mar 23;11:91
pubmed: 29628875
Ann Surg Oncol. 2017 Dec;24(13):4017-4024
pubmed: 28933054